Trial | NCT00703742  Report issue

Official Title

A Neuroimaging and Epigenetic Investigation of Antidepressants in Depression

  • Phase

    N/A

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    200
The purpose of this study is:

to find out the structural or functional effects of selective serotonin reuptake inhibitors (SSRI) in major depressive disorder (MDD);
find special abnormalities in depression secondary to other disease, e.g., autoimmune disease like systemic lupus erythematosus (SLE).
find the relationship between the efficacy of antidepressant and the change of neuroimaging in MDD
to find possible predispose to MDD
to explore the DNA methylation status in depression;
to explore the pathology of depression
to identify the difference between MDD and depression secondary to other disease ,especially autoimmune disease
to explore the effect of gene-environment interaction on the epigenetic regulation of the depression
Study Started
Jun 30
2008
Primary Completion
Jun 30
2011
Study Completion
Jun 30
2011
Last Update
Sep 17
2019

Drug Escitalopram

A,1: Escitalopram, oral, 20 mg/day, 8 weeks

A,1 Experimental

A: Escitalopram, 20 mg/day,8weeks

Criteria 

Inclusion Criteria:

DSM-IV Major Depression or Dysthymia
Age 18-65
Physically healthy
Drug-free

Exclusion Criteria:

Body metal (e.g., wire stitches, screws in bones, stainless steel hips)
History of Psychosis or Epilepsy
Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)
Bipolar I
Need for wash-out from effective treatment in order to participate
Pregnant
High suicide risk
Currently taking (within 2 weeks; 4 weeks for Fluoxetine) antidepressants
No Results Posted